Golden hamsters were administered seven anthracyclines: adriamycin (ADM), detorubicin (DTR), daunorubicin (DNR), 4’-epi-adriamycin (eADM), rubidazone (RBZ), aclacinomycin (ACM), and N-trifluoroacetyladriamycin-14-valerate (AD-32), three times a week during 4 weeks, at doses equivalent to 3/4 of those which are optimally oncostatic on murine L1210 leukemia. We examined their myocardia by electron microscopy (EM) and their skin by light microscopy (LM), and report here the findings of these two examinations.
The mortality was very high for the groups of hamsters treated with ADM, DTR, DRB, eADM, and RBZ (all treated hamsters died before the end of the fourth week) and very low for those treated with ACM and AD-32 (for each drug, only one of the 21 treated animals died after 4 weeks of treatment). After the first week of treatment and chiefly after the second week, all treated hamsters, except those treated with ACM, showed very severe EM alterations of their myocardia. EM detected almost no early myocardial lesions in ACM-treated hamsters but, after 4 weeks of treatment, severe cardiac lesions also appeared which, like those after AD-32, were nonlethal and reversible.
LM of the skin detected degenerative lesions with atrophy of all epidermic layers and a loss of the hair (alopecia) in all treated hamsters except those treated with ACM and AD-32; the skin in these two groups preserved its normal histologic structure. These observations agree with phase I-II clinical ACM studies in which the rate of ECG abnormalities was 4.5% and the rate of alopecia 0%, and with an early AD-32 clinical study conducted by Blum .
Sarcoplasmic Reticulum Golden Hamster Original Magnification Intercalate Disk Severe Alteration
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Benjamin RS, Mason YW, Billingham ME (1978) Cardiac toxicity of adriamycin-DNA complex and rubidazone: Evaluation by electrocardiogram and endomyocardial biopsy. Cancer Treat Rep 62: 935–939PubMedGoogle Scholar
Billingham MA, Mason JW, Briston MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865–872PubMedGoogle Scholar
Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei III E (1979) Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep 63:919–925PubMedGoogle Scholar
Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES (1973) Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 32:771–788PubMedCrossRefGoogle Scholar
Clarysse A, Kenis Y, Mathe G (1976) Cancer chemotherapy. Its role in the treatment strategy of hematologic malignancies and solid tumors. Springer, Berlin Heidelberg New YorkGoogle Scholar
Dantchev D, Slioussartchouk V, Paintrand M, Bourut C, Hayat M, Mathé G (1979) Electron microscopy of the heart and light microscopy of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD32 and aclacinomycin. Cancer Treat Rep 63:875–889PubMedGoogle Scholar
E.O.R.T.C. Clinical Screening Group (1980) Clinical study of detorubicin. Recent Results Cancer Res 74:194–201Google Scholar
Ferrans VJ (1978) Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62:955–961PubMedGoogle Scholar
Freireich EJ, Gehan EA, Rail DP, Schmidt LM, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50:219–245PubMedGoogle Scholar
Jacquillat CL, Auclerc MF, Weil M, Maral J, Degas L, Auclerc G, Tobelem G, Schaison G, Bernard J (1979) Clinical activity of detorubicin: a new anthracycline derivative. Cancer Treat Rep 63:889–895PubMedGoogle Scholar
Mathé G, Bayssas M, Gouveia J, Dantchev D, Ribaud P, Machover D, Misset JL, Schwarzenberg L, Jasmin C, Hayat M (1978) Preliminary results of a phase II trial of aclacinomycin in acute leukemia and lymphosarcoma. Cancer Chemother Pharmacol 1:259–262PubMedGoogle Scholar
Ogawa M, Inagaki J, Horikoshi N, Inoue K, Chinen T, Ueoka H, Nagura E (1979) Clinical study of aclacinomycin A. Cancer Treat Rep 63:931–935PubMedGoogle Scholar